Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2781-2800 of 3,900 trials

Heart Procedure: Single vs. Dual Antiplatelet Therapy

We are comparing a single medication to a combination of two medications for patients after a heart procedure. The goal is to see if the single medication is just as safe and effective while reducing bleeding risks.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Pneumococcal Vaccine Response in Patients Without a Spleen

We are studying how the timing of pneumococcal vaccination affects immune response in patients who have had their spleen removed. This research may help improve vaccination strategies for asplenic individuals.

Asplenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementAllergologyHematologyInfectious Diseases

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

First-in-Human Trial of OX118

We are testing a new drug, OX118, in healthy volunteers to evaluate its safety and effects. This study aims to gather important information before it can be used in patients.

Immune System Diseases6-12 monthsSafety phase (I)Infectious DiseasesRheumatology

Almagate for Heartburn in Pregnant Women

We are studying the safety of almagate for treating heartburn and reflux in pregnant women. The trial also examines how this treatment affects the health of the fetus and newborn.

Heartburn and Reflux>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics

Soft Tissue Sarcoma: Doxorubicin Chemotherapy Study

We are investigating whether adding doxorubicin-based chemotherapy helps patients with high-risk localized soft tissue sarcoma live longer without metastasis. This study compares it to standard treatment to assess safety and effectiveness.

Soft Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

CIDP: NVG-2089 Treatment Study

We are evaluating the safety and effectiveness of NVG-2089 for individuals with Chronic Inflammatory Demyelinating Polyneuropathy. This study aims to find out if it can help improve symptoms and overall health.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

MELAS: Testing Zagociguat

We are studying the investigational drug zagociguat to see if it helps reduce fatigue and improve thinking skills in people with MELAS. The trial also looks at its safety and effects on muscle weakness and memory.

MELAS Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Advanced Solid Tumors: ALTA2618 Treatment

We are testing a new drug called ALTA2618 for patients with advanced solid tumors that have the AKT1 E17K mutation. The goal is to see how safe it is and how it affects tumor growth.

Advanced Solid Tumors with AKT1 E17K Mutation1-2 yearsSafety phase (I)Oncology

ADHD and Depression: Dexamfetamine Formulations Study

We are investigating the safety and effectiveness of two dexamfetamine sulfate formulations for adults with ADHD and moderate to severe depression. This study aims to see how these treatments compare to a placebo in improving symptoms and managing side effects.

Major DepressionAttention Deficit Hyperactivity Disorder (ADHD)3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPsychiatry

Staphylococcus Aureus Bacteremia: Shorter Antibiotic Treatment

We are studying whether 4 weeks of antibiotic treatment is as effective as 6 weeks for patients with complicated Staphylococcus aureus bacteremia who have improved after initial therapy.

Staphylococcus aureus Bacteremia6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Mucositis in Metastatic Renal Cell Carcinoma: Folic Acid Supplement Study

We are studying whether a folic acid supplement can help reduce mucositis in patients with metastatic renal cell carcinoma receiving targeted therapy. This trial will also assess the impact on quality of life and treatment side effects.

Metastatic Renal Cell Carcinoma≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicineOncology

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

BDT272: Safety and Dosing Study

We are testing a new drug called BDT272 in healthy volunteers to see how safe it is and how the body processes it. This study will help us understand its effects before further testing.

Moderate to Severe PainSafety phase (I)Neurology

Obesity: BI 456906 vs. Semaglutide

We are testing a new medication, BI 456906, in people with obesity to see how it affects liver function compared to semaglutide. This study aims to understand the potential benefits of different doses for managing obesity.

Obesity>2 yearsSafety phase (I)EndocrinologyInternal Medicine

HIV-1 Control: Genetic and Immune Response Study

We are studying early-treated HIV-1 patients who stopped their antiretroviral therapy to find out if specific genetic and immune markers can predict their ability to control the virus. This research may help improve future treatment strategies.

HIV Positive During Acute Phase>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Erectile Rehabilitation with Sildenafil After Rectal Cancer Surgery

We are studying whether Sildenafil can help men maintain erectile function after proctectomy for rectal cancer. This trial will evaluate its effects on sexual health and quality of life over the year following surgery.

Men Treated with Proctectomy for Rectal Cancer>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncologyUrology

Gastrointestinal Stromal Tumor: Adjuvant Imatinib Study

We are studying whether adjuvant Imatinib can help prevent cancer recurrence in patients with intermediate-risk gastrointestinal stromal tumors. This trial compares its effects on survival and quality of life against standard treatments.

Gastrointestinal Stromal Tumor>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology